Keywords: gilead, viread, shows, promise, hbv, trial, california
Gilead's Viread shows promise in HBV trial
Article | 18 June 2007
California, USA-based biopharmaceutical company Gilead Sciences says that a Phase III trial of its once-daily anti-HIV drug Viread (tenofovir disoproxil ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
